BioSpace News Archive

Lyra Therapeutics, Inc. announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses.

Ipsen announced that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Products for Human Use of the European Medicines Agency confirms the negative opinion given in January 2023.

Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

Biological Dynamics announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.

Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring interim clinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody, in combination with granulocyte-macrophage colony-stimulating factor will be presented at the American Society of Clinical Oncology Annual Meeting to be held June 2-6, 2023, in Chicago, Illinois.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201.

As per the latest The Insight Partners research report, “Pharmaceutical Robots Market to 2028 – Global Analysis and Forecast – by Product, Application, End User, and Geography,”

According to our new research study on “Diabetic Foot Ulcer Treatment Market to 2027 – Global Analysis and Forecast – by Type, Ulcer Type, and End User,” the market was valued at US$ 4,580.24 million in 2021 and is projected to reach US$ 7,793.83 million by 2028; it is expected to grow at a CAGR of 7.9% during 2021–2028

According to our new research study on “Exoskeleton Robotic System Market Forecast to 2028 – COVID-19 Impact and Global Analysis

The Insight Partners published latest research study on “Coagulation Analyser Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Test, Technology, End Users, and Geography,